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Abstract
Monocytes/macrophages constitute the first line of defence for external intrusion or 
infection. Circulatory monocytes represent about 10% of leukocytes in human blood and 
resident macrophages are distributed in a variety of tissues and organs to maintain body 
homeostasis. But relatively little is known about the consequences of chronic viral infec-
tions on monocytes. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are 
the most important causes of chronic liver diseases, which may develop to serious and 
fatal liver pathology, including liver cirrhosis and hepatocellular carcinoma. Whether 
HBV and HCV infections are cleared or persist is determined by host immune responses. 
Viral replication takes place inside hepatocytes as soon as infection begins. The secre-
tion of infectious virions or virus proteins can persist for decades at high rates. Chronic 
infections with HBV and HCV are the result of ineffective anti-viral immune response 
towards the virus. Interacting with virions or virus proteins, monocytes/macrophages 
play an important function in the disease process. The role of monocytes/macrophages in 
HBV and HCV infections or co-infections is discussed in this chapter.
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1. Introduction
The significance of the innate immune response as a defence against microbial infections and 
its link to the adaptive immune responses have become increasingly recognized during the 
past few years. The activation of the innate immune response generally leads to the produc-
tion of type I IFNs. Monocytes/macrophages constitute the first line of defence for external 
intrusion or infection. Circulatory monocytes represent about 10% of leukocytes in human 
blood and resident macrophages are distributed in a variety of tissues and organs to maintain 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
body homeostasis. But relatively little is known about the consequences of chronic viral infec-
tions on monocytes.
Hepatitis B virus (HBV) infection is a major health problem that affects around 350 million 
people worldwide, despite the availability of a prophylactic vaccine [1]. The number of the 
chronic HBV infection has already beyond 240 million because a great fraction of patients is 
unable to clear the virus spontaneously, although there remain a lot of patients clearing the 
HBV virus at the early stage [2]. Up to date, chronically infected patients are at high risk of 
developing HBV-related diseases such as liver cirrhosis and hepatocellular carcinoma, which 
account for 600,000 deaths annually [3]. The interaction between the HBV and an affective 
inadequate immune response could lead a chronicity of HBV infection [4–6]. Viral replication 
takes place inside hepatocytes as soon as infection begins. The secretion of infectious virions 
or virus proteins can persist for decades at high rates. HBV DNA, HBeAg and HBsAg can 
be easily detected in serum consequently. The levels of these clinical marker means HBV 
DNA,HBsAg for clinical diagnosis levels could fluctuate for a long time and keep sistency, 
are a reflection of virus duplicate activity and used to define the patients disease stage [5, 6].
Hepatitis C virus infection is considered as the most serious cause of chronic liver disease and 
hepatocellular carcinoma worldwide in the past 50 years [7, 8]. The mechanisms by which 
host immune system lose the supervision and clear the virus are poorly understood. When 
the HCV invades the body, under the stimulation of the viral proteins, the immune system 
is accurately activated and regulates the balance between inflammatory injury and immune 
tolerance. The standard treatment with pegylated interferon and ribavirin has limited effec-
tiveness for the most prevalent viral genotypes (1a/1b) in the U.S in the past years, but the 
direct-acting anti-viral (DAA) treatment could enhance the effectiveness greatly [9]. While the 
unaffordable cost and the drug resistance also restrict its widespread use. Unlike HBV infec-
tion, no vaccine is currently available to prevent the HCV infection, which is a serious prob-
lem we must confront. To understand the HCV-host interactions that lead to viral persistence 
will help vaccine development and new drug design. The exact mechanism by which HBV 
escapes immunity is still not known. Interacting with virions or virus proteins, monocytes/
macrophages play an important function in the disease process. The role of monocytes/mac-
rophages in HBV and HCV infections is discussed in this chapter.
2. Monocytes/macrophages in HBV infection
Monocytes originated in the bone marrow mainly consist of a part of the innate immune sys-
tem. Being the first immune barrier, monocytes play multiple roles in the immune system 
[10]. Such roles include: (1) act as a pool of precursor cell, which replenish to resident mac-
rophages and dendritic cells as soon as needed, and (2) in response to signals of cytokines or 
chemokines, monocytes can be recruited and migrated to the sites of infected tissues quickly 
and divided/differentiated into local inflammatory macrophages and dendritic cells to trigger 
an immune response [11]. Whether HBV infection is cleared or persists is determined by host 
immune responses [7]. Viral replication takes place inside hepatocytes as soon as infection 
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begins. The secretion of infectious virions or virus proteins can persist for decades at high 
rates. Hepatitis B virus (HBV) DNA, HBeAg and HBsAg can be easily detected in serum con-
sequently. The levels of these clinical marker means HBV DNA, HBsAg for clinical diagnosis 
could fluctuate for a long time and keep sistency, are a reflection of virus duplicate activity and 
used to define the patients disease stage [9].
Circulating monocytes represent about 10% of mononuclear cells in human peripheral blood. 
Although involving in acute inflammation and wound, relatively little is known about the 
chronic viral infections on monocytes [12]. One research found that the function of monocytes 
were impaired in HIV and HCV infection, because of the responsiveness of TLRs [13–15], and 
Toll-like receptor responsiveness of monocytes in chronic HCV infections [14, 15]. Based on 
the surface of CD14 and CD16 expression, researches divided monocytes into two distinct sub-
populations. CD14+ CD16+ monocytes, which occupy 10–20% of total blood monocytes and 
produces much more pro-inflammatory cytokines by the stimulation of TLRs ligands, such as 
TNF and IL-1β. The majority of CD14(high)CD16– (80–90%) monocytes have been reported to 
produce relatively high IL-10 and weak TNF [16, 17]. Hepatitis B surface Ag (HBsAg), as a main 
HBV protein, has been reported to suppress the activity of monocytes through binding to the 
monocytes. The binding to monocytes was enhanced by a heat-labile serum protein that was 
inhibited by Ca2M/Mg2M, low pH and an HBsAg-specific monoclonal antibody [18]. Hepatitis B surface Ag (HBsAg) inhibits monocytes inflammatory response by means of COX-2 depen-
dence and may regulate natural killer (NK) cell function interfering IFN-γ production by inhib-
iting IL-18 and IL-12 production [19]. Hepatitis B surface Ag (HBsAg) is the most abundant 
HBV protein in the liver and in the peripheral blood of chronic hepatitis B (CHB) patients, which 
can accumulate up to 100 mg/mL in the peripheral blood, and typically outnumbers infectious 
virions by 1000:1 to 10,000:1 [20]. The high concentration of HBsAg in the blood stream of CHB 
patients could theoretically contribute to the hampered immune response. Several studies have 
shown that HBsAg can suppress the release of LPS-induced cytokines in human monocytes 
by interfering with the TLR signal pathway [21]. These results suggest that HBsAg could be 
consumed in the macrophages or Kupffer cells (KCs) (shown in Figure 1) and alter the innate 
immune response, which may contribute to the establishment of chronic infections.
Monocyte subset frequencies are altered depending on the clinical phase of the chronic 
HBV infection [23]. Moreover, HBeAg also plays a regulating action in the HBV  infection. 
Figure 1. KCs uptake of HBsAg (green) in vitro imaged by confocal microscopy [22].
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Expression of TLR2 correlates with HBeAg concentration negatively in CHB patients. 
Stimulation with TLR2 agonists in vitro peripheral blood mononuclear cell (PBMC) from 
HBeAg-positive patients produced less TNF and IL-6 compared to HBeAg-negative patients 
[24, 25]. Furthermore, exposure of monocytes to HBsAg suppressed LPS-induced TNF and 
IL-1β production in vivo and in vitro [26, 27]. Hepatitis B surface Ag (HBsAg) was related 
to decreased cytokine production induced by the TLR2 ligand (Pam3csk4) in PBMCs from 
chronic hepatitis B patients in vivo [28]. The later research demonstrates that HBsAg selec-
tively inhibits Pam3csk4-stimulated IL-12 production. The mechanism study shows that 
HBsAg could inhibit JNK-MAPK pathway and provides a mechanism by which HBV evades 
immunity and maintains its persistence [21].
Kupffer cells (KCs) are the most important innate immune cells in the liver and constitute 
more than 80% of tissue resident macrophages in the body. Kupffer cells (KCs) account for 
about 15% of total liver cells, which are more than T cells and liver NK cells. Acting as scaven-
ger cells, KCs remove particulate material from the portal circulation, which has been studied 
for a long time [29]. Viral infections have been implicated with the KCs in the pathogenesis of 
inflammatory liver diseases recently [30]. The KCs play an important role in liver injury when 
the liver is infected by HBV [31].
The liver is continuously exposed to non-pathogenic antigens (from food) and to gut derived 
lipopolysaccharide (LPS). The LPS is a powerful stimulus for innate immunity through TLR 
ligation and similarly activates professional antigen-presenting cells (APCs). Kupffer cells 
modulate the host immune response by the elaboration of IL-10. However, the pro-inflamma-
tory cytokines (IL-12, IL-15 and IL-18) secreted by the Kupffer cells could stimulate NK cell 
function for secreting IFN-γ [32]. Kupffer cells (KCs) are intravascular macrophages that are 
continuously exposed to, and tolerant of, bacterial TLR ligands, which are delivered via the 
portal circulation.
In HBV infection, Kupffer cells participate in many immune responses, including immune 
cell activation, anti-viral immunity and tissue damage repair [33]. The immune cells cross 
talk occurs in the infected liver. Kupffer cells regulate T-cell responses by means of the co-
stimulatory molecules CD80 and CD86, which are expressed on the cell surface [34]. The 
ligands of the two molecules on the T cells are CD28 and CTLA-4, respectively. CD86 on 
APCs stimulates T cells by binding CD28, which occurs before CD80 up expression. CD80 
has a higher ability to initiate inhibitory signals through its interaction with CTLA-4 [35–37]. 
On the other hand, CD80 and CD86 regulate T helper cell differentiation and control adaptive 
immunity. CD80 mainly drives T-cell differentiation towards a Th1 profile and CD86 leads 
the differentiation towards a Th2 profile [38–42]. T-cell response in HBV infection mainly ini-
tiates Th2 immune response rather than Th1. The production of IL-10 was reported in many 
researches but the Th1 responses and cytokine production are weak when compared with 
resolver [43, 44].
Kupffer cells (KCs) and infiltrating monocytes/macrophages are main APCs to regulate 
adoptive immune response but must avoid hyper-activation of the immune system through 
expressing inhibitory molecules PD-L1 and PD-L2. The levels of PD-L1 and CD80/CD86 sig-
nals on APCs control the magnitude of T-cell activation [45–47]. One study has investigated 
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the expression of CD80 and CD86 on KCs in HBV infection. This study found that only few 
KCs express these molecules [48]. The different expressions of CD80, CD86 and PD-L1 in KCs 
in the portal areas of the liver were explored together with the correlation of their expressions 
with the fibrosis score and grade of inflammation during HBV infection. The HBV virus and 
the protein function on monocytes/macrophages are listed in Table 1.
3. Monocytes/macrophages in HCV infection
Hepatitis C virus (HCV) is also a cause of serious liver diseases as well as other extra hepatic 
pathologies especially in the developed countries. A classical combination of the drugs 
pegylated interferon and ribavirin used as standard treatment for decades. Recently, some 
other drugs have been approved that may enhance the effectiveness to a great extent. These 
drugs are designed to block the virus duplication by interfering with specific viral proteins. 
Rational therapies and effective vaccine can be designed if HCV replication is understood 
totally. Monocytes appeared to contain the core protein of HCV by flow cytometry in vitro 
infected experiment, suggesting that HCV was inside the monocytes [49]. Different types of 
monocytic cell lineages have been investigated, with CD14+, CD16++ and CD14++, CD16++ but 
not with CD14+, CD16– cells being found infected [50]. These studies suggest that different cell 
types allow replication of slightly different versions of HCV.
Monocytes are not only infected by HCV virions, but also influenced by virus proteins. 
Chronic activation of monocytes and macrophages is seen in HCV and correlates with liver 
damage [51, 30]. Monocytes had the highest gal-9 levels in chronically infected HCV patients 
suggests that they may be a source of T cell inhibitory gal-9 in HCV infection. Toll-like recep-
tors (TLR) have a critical role in innate immunity against pathogens. During chronic HCV 
infection, interleukin-12 (IL-12) produced by monocytes/macrophages is significantly sup-
pressed. Programmed death-1 (PD-1), an inhibitory receptor on immune cells, plays a piv-
otal role in suppressing T-cell responses during chronic viral infection. IL-12 production 
decreased on monocytes/macrophages in HCV infection correlates the up-regulation of PD-1 
on cell surface. IL-12 production resumed when PD-1/PD-L1 antibody or IFN/RBV treatment 
was carried out. The possible mechanism is that the STAT-1 phosphorylation is enhanced 
during the treatment [52]. Tim-3, acting as a negative regulator, inhibits monocytes’/macro-
phages’ function in HCV infection in some researches [53].
Virus/protein Cell receptor Cell signal Cytokines
HBsAg TLR2 MAPK/JNK IL-12
TLR4 PI3K TNF-a, IL-1b
HBeAg TLR2 C-Jun/JNK TNF-a, IL-6
HBVcore TLR2/4 PI3K/JNK TNF-a, IL-6,IL-12
HBV DNA TLR7/9 RGI IL-12, IL-18
Table 1. Monocytes’/macrophages’ function in HBV infection.
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Myeloid-derived suppressor cell (MDSC) is a kind of inhibitory cell that originated in the 
bone marrow and was first identified as natural suppressor cell in tumour-bearing mice in the 
mid-1960s [54]. Myeloid-derived suppressor cell (MDSC) originated in the bone marrow and 
later differentiated/divided into granulocytes, macrophages or mature dendritic cells [55, 56]. 
Myeloid-derived suppressor cell (MDSC) migrates or accumulates in the tumours, spleen, 
bone marrow and blood under different pathological conditions. Based on the different cell 
surface markers and cell origin, the MDSC can be divided into monocyte (Mo), granulocyte 
and endothelial-committed subsets. Myeloid-derived suppressor cell (MDSC) represents a 
cell type that suppresses the function of other immune cells and creates a suppressive envi-
ronment. Studies revealed that MDSC numbers correlate with T-cell frequency inversely in 
the peripheral blood [57]. T-cell responses can be suppressed by MDSCs through numerous 
mechanisms [58–60]. In patients with HCV infection, T-cell function is impaired according 
to the clinical observation. Hepatitis C virus (HCV) core protein and polyI:C induce TNF-α 
(pro-inflammatory cytokine), IL-10 (immunomodulatory cytokine) and IFN-γ (anti-viral cyto-
kine) secretions from monocytes. Then, monocytes are reprogrammed to acquire or lose the 
immunosuppressive (MDSC) phenotype through these cytokines. Hepatitis C virus–induced 
Mo-MDSC production was attributed to the PI3K pathway via induction of IL-10 and TNF-α 
secretion [61]. The HBV virus and the protein function on monocytes/macrophages are listed 
in Table 2.
4. Monocytes/macrophages in HBV/HCV co-infection
Despite their different replication strategies and life cycles, HBV and HCV have similar 
modes of transmission through bodily fluid, and both have developed highly successful 
ways to establish chronic hepatitis [62]. Liver injury and disease progression are thought to 
be driven by the interaction between viruses and host immune responses in both infections 
[63–66]. Given their similar modes of transmission, HBV/HCV co-infection occurs frequently 
in endemic areas although its prevalence is exactly unknown [67]. Between 2 and 10% of anti–
HCV-positive patients also test positive for HBsAg, while 5–20% of patients with chronic HBV 
infection test positive for anti-HCV antibodies [68]. It has been reported that HBV/HCV co-
infection leads to more severe liver disease and a higher prevalence of liver cancer than non-
infection [69], but an inverse relationship between the replication of each virus within some 
co-infected patients has been noted [70–74]. Hepatitis B virus-Hepatitis C virus  co-infection 
Virus/protein Cell receptor Cell signal Cytokines
HCVcore TLR2 MYD88 IL-6, IL-10
HCV RNA TLR7/8 CD81 IL-1b, IL-12
HCV dsRNA TLR3 ISG15/56 IFNα/β
NS3 TLR2 RGI IL-1b, IL-6, TNF-α
Table 2. Monocytes’/macrophages’ function in HCV infection.
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involves complex viral interaction; HBV and HCV can replicate in the same cells in vitro with 
no evidence of interference between them [75, 76]. Therefore, the viral interference observed 
in HBV/HCV co-infected patients in vivo is probably due to indirect mechanisms mediated by 
innate and/or adaptive host immune responses.
Hepatitis B virus-Hepatitis C virus co-infection is a blank field because of lack of robust cell 
and animal experimental model. Our research group attempts to do some basic experiments 
in HBV-HCV co-infection. Human primary peripheral blood monocytes were cultured for 2 
days in increasing concentrations of infectious HCV, infectious HBV or both viruses together. 
As expected, the HCV, HBV and the two viruses together suppressed the expression of 
HLA-DR and TRAIL on monocytes, and increased the expression of PD-L1 and the secretion 
of IL-10, similar to the effects of recombinant HCV. In addition, we also uncovered previously 
unknown immune suppressive effects in both HCV and HBV, and the two viruses together 
strongly suppressed the expression of genes encoding stat1 and stat2, thereby disabling IFN 
signalling. These findings help to explain the well-known propensity of both HCV and HBV 
to induce T-cell immune suppression and clonal exhaustion, but they do not explain the anti-
HCV effect of HBV infection in vivo. Other cell types, or cytokines, or both, may be playing a 
role in association with HBV mediated suppression of HCV.
To identify cytokines that were secreted in response to HBV, but not HCV, we performed 
experiments in which viruses were titrated either alone, or against a fixed concentration of the 
other virus, and observed that HBV induced IL-1β and IL-12 secretion, while HCV did not. 
Furthermore, the presence of HCV did not suppress the induction of either IL-1β or IL-12 by 
HBV. Since cytokine expression is regulated by a number of genes, we next measured the expres-
sion level of the associated genes. We observed novel emergent properties when the two viruses 
were combined. That is, Nfkb1 was not induced by HBV alone. It was induced by low concen-
trations of HCV, but then suppressed by higher concentrations. However, with HCV and HBV 
combined, the expression of this gene was sustained across a wide range of viral titers. Similarly, 
the Ifr1 gene was not affected by HBV alone but was modestly elevated by HCV, but drastically 
elevated with HCV and HBV combined. The secretion of TNF-α was strongly induced by HBV, 
but not by HCV, and modestly suppressed in the presence of both viruses together. Based on 
experiments in which human blood monocytes were exposed to intact HBV, intact HCV, or both 
viruses together, our results showed that both viruses exert strong immunosuppressive effects.
5. Perspectives
Our understanding of the role of monocytes/macrophages in HBV or HCV is far from com-
pletion. Nevertheless, the anti-viral roles of monocytes/macrophages will be appreciated 
by binding and/or uptake of virus leading to immune recognition and the production of 
pro-inflammatory or anti-inflammatory mediators resulting in (1) activation of neighbour-
ing cells, such as NK cells and CD8+ T cells, (2) blockage in viral replication in hepatocytes 
and (3) attraction, activation and interaction with other immune cells, including ILCs, pDCs 
and Tregs, which will further increase the anti-viral and inflammatory response. In the early 
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phases after infection, the immune activating roles of monocytes/macrophages are beneficial 
to help the body cause anti-virus response and clear virus and dead cell. But the situation 
will turn to the other side if the infection develops into chronic. The strong immune activity 
may also contribute to tissue damage and the development of fibrosis, cirrhosis and HCC. 
Furthermore, immune regulatory functions of monocytes/macrophages have been described, 
which may counteract the development of effective anti-viral immunity and support viral 
persistence and related disease pathogenesis.
Intrahepatic macrophages become an interesting and complex cellular target for treatment 
options and hot point in viral hepatitis with the growing appreciation of the roles of intrahe-
patic macrophages in both protective and harmful responses. With the development of flow 
and cell sorting technology, identifying phenotypical and/or functional characteristics discrim-
inating KC from infiltrating macrophages will become easy day after day. Despite the existence 
of a HBV, vaccine is used widely but the already HBV infected population also be at high risk of 
developing to liver fibrosis and liver cancer. The standard treatment with pegylated interferon 
and ribavirin has limited effectiveness for the most prevalent viral genotypes (1a/1b) in the 
U.S in the past years, but the DAA treatment could enhance the effectiveness greatly. Also, the 
unaffordable price and the drug resistance also restrict its widespread use. Unlike HBV infec-
tion, no vaccine is currently available to prevent HCV, which is a serious problem we must con-
front. To understand the HCV-host interactions that lead to viral persistence will help vaccine 
development and new drug design. The exact mechanism of monocytes/macrophages in HBV 
and HCV infection will provide us new insight into and confidence to overcome the virus.
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